| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8757458 | Contemporary Clinical Trials | 2018 | 9 Pages |
Abstract
EMPIRE-CF is expected to identify the optimal patient population, dose, duration and endpoints for future acebilustat trials, and widen understanding of the drug's efficacy in patients with CF.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
J. Stuart Elborn, Sanjeev Ahuja, Eric Springman, John Mershon, Ralph Grosswald, Steven M. Rowe,